Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with Beijing Mabworks Biotech Co., Ltd to collaborate in biomedical technology services and new drug development. The partnership will cover drug discovery, process R&D, production, quality control, and clinical research through joint development, commissioned R&D, technical exchanges, and special projects.
Agreement Details
The agreement specifies that technical achievements and related intellectual property rights from the collaboration will belong to the party that completes them independently, unless otherwise agreed. Science Sun also plans to make a long-term investment in Mabworks. The agreement is valid for three years with an option to extend.
Previous Collaboration
In September 2021, Science Sun engaged Mabworks’ wholly-owned subsidiary Mabridge to provide pharmaceutical research and BLA filing services during the clinical phase of the K11 program.-Fineline Info & Tech
